


Table 21. The inhibitory effect of compounds (28, 30) on TNF-a formation in medium



Cell line: Raw 264.7 cells

Inducer: LPS (1 µg/ml)

Cell line: N9 cells


Inducer: LPS (10 ng/ml)+ IFN-γ (10 U/ml)

No.	Conc. (µM)	R ₂ '	R ₄ ''	TNF-a formation (ng/ml)			
				RAW	% inhibition	N9	% inhibition
	Control			145.4 ± 6.3		2.12 ± 0.12	
28	10	Cl	F	--	--	2.58 ± 0.08	-21.9 ± 3.2
	30			131.4 ± 9.0	10.3 ± 0.4		Cytotoxic
30	10	Cl	H	--	--	2.45 ± 0.18	-15.2 ± 2.3
	30			112.7 ± 8.6*	22.7 ± 3.7*		Cytotoxic
SB203580							
	3			132.8 ± 3.3	8.9 ± 7.2	1.33 ± 0.04**	36.4 ± 3.3**
	10			107.2 ± 1.3**	26.5 ± 6.0**	1.02 ± 0.17**	51.6 ± 7.6**
	30			60.9 ± 5.3**	58.2 ± 2.4**	0.97 ± 0.10**	53.5 ± 4.3**
	IC₅₀			22.4 ± 3.4 µM		10.2 ± 1.6 µM	

* $P < 0.05$, ** $P < 0.01$; N = 3; --, not determined

SB203580: [4-(4-Fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)1H-imidazole: positive control

Table 22. The inhibitory effect of compounds (31-33, 35-37, 39, 40) on TNF- α formation in medium



Cell line: Raw 264.7 cells

Inducer: LPS (1 μ g/ml)

Cell line: N9 cells


Inducer: LPS (10 ng/ml)+ IFN- γ (10 U/ml)

No.	Conc. (μ M)	R ₆	R ₂ '	TNF- α formation (ng/ml)			
				RAW	% inhibition	N9	% inhibition
Control				145.4 \pm 6.3		2.12 \pm 0.12	
31	30	Cl	F	156.8 \pm 2.6	-7.4 \pm 3.9	1.29 \pm 0.16**	39.4 \pm 4.0**
32	3	Cl	Cl	--	--	1.33 \pm 0.07**	36.6 \pm 3.5**
	10			--	--	0.96 \pm 0.08**	54.2 \pm 5.8**
	30			134.9 \pm 2.2	7.5 \pm 4.3	0.58 \pm 0.09**	72.4 \pm 5.7**
IC₅₀				8.4 \pm 2.8 μM			
33	30	Cl	OCH ₃	140.1 \pm 3.4	4.0 \pm 5.0	1.50 \pm 0.17*	29.5 \pm 4.2*
35	30	F	F	141.8 \pm 3.3	2.3 \pm 1.9	1.69 \pm 0.03	19.9 \pm 3.3
36	30	F	Cl	132.7 \pm 1.4	8.5 \pm 3.0	1.13 \pm 0.01**	46.3 \pm 2.4**
37	30	F	OCH ₃	175.6 \pm 2.8	-21.0 \pm 3.3	1.92 \pm 0.08	8.9 \pm 3.1
39	30	OCH ₃	F	128.3 \pm 3.9	11.7 \pm 2.1	1.79 \pm 0.11	15.7 \pm 1.7
40	3	OCH ₃	Cl	--	--	1.54 \pm 0.04*	26.7 \pm 3.4*
	10			--	--	1.37 \pm 0.08*	35.1 \pm 5.4*
	30			90.6 \pm 1.3**	38.1 \pm 4.9**	0.88 \pm 0.09**	57.3 \pm 5.3**
IC₅₀				22.3 \pm 6.4 μM			
SB203580							
	3			132.8 \pm 3.3	8.9 \pm 7.2	1.33 \pm 0.04**	36.4 \pm 1.3**
	10			107.2 \pm 1.3**	26.5 \pm 6.0**	1.02 \pm 0.17**	51.6 \pm 7.6**
	30			60.9 \pm 5.3**	58.2 \pm 2.4**	0.97 \pm 0.10**	53.5 \pm 4.3**
IC₅₀				22.4 \pm 3.4 μM		10.2 \pm 1.6 μM	

* $P < 0.05$, ** $P < 0.01$; N = 3; --, not determined

SB203580: [4-(4-Fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)1H-imidazole: positive control

Table 23. The inhibitory effect of compounds (43, 44) on TNF- α formation in medium



Cell line: Raw 264.7 cells

Inducer: LPS (1 μ g/ml)

Cell line: N9 cells


Inducer: LPS (10 ng/ml)+ IFN- γ (10 U/ml)

No.	Conc. (μ M)	R ₆	R ₂ '	TNF- α formation (ng/ml)			
				RAW	% inhibition	N9	% inhibition
Control				145.4 \pm 6.3		2.12 \pm 0.12	
43	0.1	F	F	--	--	1.21 \pm 0.09**	42.6 \pm 5.9**
	0.3			--	--	0.99 \pm 0.10**	53.3 \pm 7.0**
	1			--	--	0.30 \pm 0.06**	85.5 \pm 4.4**
	3			--	--	Cytotoxic	
	10			--	--	Cytotoxic	
	30			154.6 \pm 7.2	-6.2 \pm 0.3	Cytotoxic	
	IC₅₀				0.19 \pm 0.06 μM		
44	0.1	OCH ₃	Cl	--	--	1.83 \pm 0.02	13.6 \pm 0.7
	0.3			--	--	1.70 \pm 0.08	20.0 \pm 4.8
	1			--	--	0.83 \pm 0.03**	60.5 \pm 1.5**
	3			--	--	Cytotoxic	
	10			--	--	Cytotoxic	
	30			162.5 \pm 6.8	-11.8 \pm 2.7	Cytotoxic	
	IC₅₀				0.66 \pm 0.02 μM		
SB203580							
	3			132.8 \pm 3.3	8.9 \pm 7.2	1.33 \pm 0.04**	36.4 \pm 1.3**
	10			107.2 \pm 1.3**	26.5 \pm 6.0**	1.02 \pm 0.17**	51.6 \pm 7.6**
	30			60.9 \pm 5.3**	58.2 \pm 2.4**	0.97 \pm 0.10**	53.5 \pm 4.3**
IC₅₀				22.4 \pm 3.4 μM		10.2 \pm 1.6 μM	

* $P < 0.05$, ** $P < 0.01$; N = 3; --, not determined

SB203580: [4-(4-Fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)1H-imidazole: positive control

Table 24. The inhibitory effect of compounds (45-47, 49-51, 53, 54) on TNF- α formation in medium



Cell line: Raw 264.7 cells

Inducer: LPS (1 μ g/ml)

Cell line: N9 cells

Inducer: LPS (10 ng/ml)+ IFN- γ (10 U/ml)

No.	Conc. (μ M)	R ₆	R ₂ '	TNF- α formation (ng/ml)			
				RAW	% inhibition	N9	% inhibition
Control				145.4 \pm 6.3		2.12 \pm 0.12	
45	30	Cl	F	172.7 \pm 5.1	-18.9 \pm 2.3	1.91 \pm 0.21	10.4 \pm 5.1
46	30	Cl	Cl	148.7 \pm 6.5	-2.0 \pm 1.3	2.14 \pm 0.16	-0.7 \pm 2.0
47	30	Cl	OCH ₃	137.5 \pm 6.7	5.4 \pm 1.6	2.05 \pm 0.18	3.4 \pm 3.8
49	30	F	F	144.7 \pm 6.0	0.4 \pm 0.6	2.14 \pm 0.12	-0.7 \pm 1.4
50	30	F	Cl	156.7 \pm 0.1	-7.5 \pm 3.5	2.28 \pm 0.09	-7.8 \pm 2.3
51	30	F	OCH ₃	169.1 \pm 1.5	-16.0 \pm 3.2	2.15 \pm 0.07	-1.6 \pm 2.7
53	30	OCH ₃	F	134.6 \pm 4.6	8.4 \pm 4.0	1.67 \pm 0.12	21.3 \pm 1.3
54	30	OCH ₃	Cl	127.8 \pm 5.8	12.0 \pm 1.8	2.15 \pm 0.28	-0.4 \pm 7.9
SB203580							
	3			132.8 \pm 3.3	8.9 \pm 7.2	1.33 \pm 0.04**	36.4 \pm 1.3**
	10			107.2 \pm 1.3**	26.5 \pm 6.0**	1.02 \pm 0.17**	51.6 \pm 7.6**
	30			60.9 \pm 5.3**	58.2 \pm 2.4**	0.97 \pm 0.10**	53.5 \pm 4.3**
	IC₅₀			22.4 \pm 3.4 μM		10.2 \pm 1.6 μM	

* $P < 0.05$, ** $P < 0.01$; N = 3

SB203580: [4-(4-Fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)1H-imidazole: positive control